The TRIAD clinical trial in aging dogs is designed to detect a 15% change in lifespan within a three-year window.

“the study that we want to do is a five-year study with rapamycin and and certainly this is scalable right so so what we have designed is a study with rapamycin”

“the way that we're planning the study now is that we will partner with five to seven veterinary schools around the United States”

“15 might be a high bar uh but it you know it's it's consistent with the lower end of what people see in mice so the first study at the low low dose of rapamycin and mice from the itp had a 14 effect i think in females and a 9 effect in males subsequent studies at higher doses had larger effects”

“the first clinical trial is with rapamycin and so that's our first shot on goal”

“i think this is the first clinical trial that has lifespan you know in a healthy or normal health status population as the endpoint”

“we've designed the the rapamycin the test of rapamycin in aging dogs or triad that's that's what we call our clinical trial we've designed triad so that we'll be able we'll be powered statistically powered to detect a 15 change in in lifespan within a three year window right so we can do a three year clinical trial reasonable cohort sizes to see an effect on lifespan”

“I say Well when Matt cabin's uh dog study reads out if it's positive I'll take rap meon”

“I've been involved as you know for a while now with a project called the dog aging project which Daniel promislo Kate creevy and myself um started depending on how you want to do the math somewhere between seven and 12 years ago um with the idea you know sort of around what what we've already discussed that there's a good rationale for companion dogs pet dogs in particular as a model for the biology of Aging but also to be able to assess Ramy specifically for its impact on lifespan and healthspan metrics because we can actually design a clinical trial and this is a real clinical trial double blind randomized Placebo controlled Veterinary clinical trial to answer the question does rap ayon slow aging increase lifespan improve multiple healthspan metrics in a reasonable time frame so we set out to design such a clinical trial we call it the test of rapy and aging dogs”

“this is a trial that will ultimately enroll 580 dogs half get Placebo half get WAP aice the treatment period is 3 years”

“with that cohort size that uh length of treatment we are powered to detect a 9% change in lifespan”

“I would be shocked if we see a shortening of lifespan from Rapa mice and treatment just given everything that I know to this point in mice and the data we've gotten so far in dogs”

“so with that cohort size that uh length of treatment we are powered to detect a nine percent change in lifespan which is important”

“so I've been involved as you know for a while now with a project called the dog aging project which Daniel promisedlo Kate cravy and myself started depending on how you want to do the math somewhere between seven and 12 years ago with the idea you know sort of around what what we've already discussed that there's a good rationale for companion dogs pet dogs in particular as a model for the biology of Aging but also to be able to assess rapamycin specifically for its impact on lifespan and health span metrics”

“so we set out to design such a clinical trial we call it the test of rapamycin and aging dogs we've done two shorter term pilot trials also double-blind placebo-controlled to establish safety to kind of work out dosing and then started the larger clinical trial Triad a few years ago which unfortunately coincided with the beginning of covid-19 so that was challenging but we've continued to work through that under making progress and so this is a trial that will ultimately enroll 580 dogs half get Placebo half get rapamycin the treatment period is three years”

“some of that work I think needs to be done in other animal models such as what Matt cllin is doing in the dog aging project um and some of that worm some of that work actually is going to need to be done in humans using biomarkers that have yet to be developed”